Objective: To facilitate collection of cumulative data on longitudinal HIV disease outcomes during HIV prevention studies by developing recommendations for follow-up of the relatively few study participants with breakthrough infections.
Introduction
The natural history of HIV infection has been an area of intense study since the start of the epidemic. Initially, and throughout the epidemic, HIV-1 seroconverters were followed longitudinally to describe the clinical, virological, and immunological trajectory of treated [1, 2] and untreated HIV disease [3] [4] [5] [6] and transmission [7] . Early studies also focused on psychosocial and behavioral factors associated with HIV transmission and infection [8, 9] . Long-term follow-up of HIV-infected individuals in natural history studies sheds light on issues such as host genetic factors of resistance and long-term nonprogression [10, 11] , the impact of treatment on disease progression [12] , HIV-1 transmission during and after seroconversion [13] , and the effects of a positive test on sexual risk behavior [14] . Some groups followed seroconverters within the context of breakthrough infection studies conducted in high-risk populations not exposed to biomedical preventions to meet a variety of study objectives [15] [16] [17] [18] , and pathogenesis work during acute infection and long-term follow-up has elucidated the concept of 'founder viruses' in the establishment of HIV infection [19, 20] .
As it became clear that CD4 þ T-cell counts [21, 22] and plasma HIV RNA [22, 23] during the first 6 months of infection were strong predictors of disease progression [24] , the need for expensive long-term follow-up of seroconverters in HIV-1 prevention clinical trials was reduced for a time. For example, the HIV Prevention Trials Network's HPTN 052, which showed that antiretroviral therapy (ART) drastically reduces the sexual transmission of HIV in heterosexual serodiscordant couples [25] , did not follow seroconverters after obtaining initial samples and assessments. Also, behavioral prevention studies have not typically needed long-term follow-up of seroconverters to obtain study endpoints, which focused on the primary endpoint -incident HIV infection [26, 27] .
More recently, however, vaccine and preexposure prophylaxis (PrEP) studies have sought to understand the effects of biomedical interventions on correlates of disease progression [28, 29] . In addition, as HIV-infected individuals age, describing development of HIV-associated non-AIDS-related conditions in these cohorts of seroconverters who received PrEP and/or a vaccine may become important. Elucidating the correlations of HIVassociated inflammation will also require longitudinal data from seroconverters from diagnosis through ART. Increasingly, answering these contemporary research questions requires the short-and long-term follow-up of study participants who become infected with HIV-1 [30] , especially in phase 3 trials of partially effective biomedical prevention modalities.
Some networks, such as the HIV Vaccine Trials Network (HVTN) [31, 32] and the Microbicide Trials Network (MTN) [33] , have already developed studies for the longterm study of participants who seroconverted while in follow-up during late phase prevention trials. However, harmonization of study protocols that follow seroconverters in such a way that would allow for cross-study analysis remains a challenge. Depending on the nature of the study question, standardizing follow-up, and collection of data at key postinfection time points may yield increased statistical power, but more importantly it would create an opportunity to ask overarching questions about the course of HIV infection in individuals who participated in prevention trials, such as development of drug resistance, change in risk behavior, secondary transmission, and development of non-AIDS-related complications. The ability to ask these questions in a systematic fashion will inform design of future intervention studies and demonstration projects. We therefore conducted a comparative analysis of recent or current HIV biomedical prevention studies to answer the questions: How can retention of participants who acquire HIV in a prevention study and enroll in a seroconverter study be maximized; What study objectives can and should be answered by the short-term and long-term follow-up of seroconverters; and, Which biological specimens and assessments can and should be recommended for all studies that follow seroconverters.
Methods
The leaders of the National Institutes of Health (NIH)funded HIV/AIDS clinical trials networks requested that the Office of HIV/AIDS Network Coordination (HANC) convene senior representatives of study teams of network prevention studies that follow seroconverters [31] [32] [33] [34] [35] [36] [37] [38] to compare and contrast consent and retention approaches, objectives, evaluations, and sample collections, and to prepare recommendations. The Seroconverter Study Group (SSG), comprised eight members, held a total of nine teleconference discussions during which the protocols were reviewed and recommendations were developed. Non-network prevention studies were also considered and senior representatives of these protocols were invited to join group discussions on an ad hoc basis [39] [40] [41] [42] [43] .
Results

Study design and operational details
A total of 15 studies that follow seroconverters were reviewed and compared. Table 1 provides an overview of these studies and Table 2 compares the aspects of study design that pertain to seroconversion. The studies represented a wide variety of prevention modalities, including microbicides, oral PrEP, and vaccines in phase 1 to 3 testing. Duration of follow-up postseroconversion differs from study to study. In some cases, seroconverters are followed for a limited time in the 'parent' study (e.g., MTN-003) before or while being transferred to a separate 'rollover' study that only follows seroconverters (e.g., MTN-015); in other cases, the seroconverters are followed entirely within the parent study [e.g. Iniciativa Profilaxis Preexposicion (Prexposure Prophylaxis Initiative) iPrEx] (see Table 2 ).
Seroconverter rollover studies typically enroll seroconverters from the parent study as soon as possible after HIV diagnosis. However, the timing is usually flexible to allow for maximum enrollment. The duration of follow-up also varies. Although perhaps for different reasons, both vaccine and biomedical studies follow seroconverters after ART initiation.
The method used to determine HIV diagnosis, infection, or seroconversion ( 
Objectives
We compared the objectives for each study (Table 4 ). Some interpretation and generalization was necessary to develop a meaningful comparison. The most common objectives, which were to describe/compare the virological, immunological, and clinical course of disease and to assess drug resistance, are shown in Table 4 along with three other objectives pertaining to behavioral outcomes, evaluation of response to ART and development of specimen repositories, which were less common but of particular interest to the SSG. There were also a variety of virological, immunological, mutation/drug resistance, and other objectives that were used in only one or two studies; these additional objectives typically related to the intervention type (see Supplemental Digital Content 1 and 2, http://links.lww.com/QAD/A297, detailed objectives of each protocol).
Assessments and samples
Assessments and samples collected were reviewed for each study ( Table 3) . Whole blood, serum/plasma, and peripheral blood mononuclear cells (PBMC), at least one type of genital or rectal secretion or biopsy, and urine samples were commonly collected. Although few protocols included study objectives specific to behavior, most studies conducted ongoing behavioral assessments. Only three studies included study objectives for development of specimen repositories, but all studies collected at least serum/plasma for storage.
The frequency and volume of blood draws varied across protocols, but the trends were similar. Clinic visits and blood draws are frequent in the weeks and months following HIV diagnosis and become less frequent as time passes. The most intense period of follow-up is typically the first 3 months. See Supplemental Digital Content 3, http://links.lww.com/QAD/A297 for more detailed information about the frequency of HIV testing and visits. 
Discussion
Various organizations conducting HIV prevention trials have been committed to following individuals who seroconvert while enrolled in HIV prevention studies by either incorporating 3-38 months of follow-up into the parent study or offering enrollment in a separate seroconverter rollover study. Such studies have enabled evaluation of clinical, immunological, virological, drug resistance, and other outcomes. A common protocol design and/or common protocol, such as a networkspecific or cross-network seroconverter study for the long-term follow-up of study participants who seroconvert while participating in a prevention study, can ease aggregation of data. A common protocol design would need to consider consent, retention, study objectives, sample collections and assessments, and consistent determination and use of diagnosis, estimated infection, and/or estimated seroconversion dates. For advancing the greater HIV prevention research agenda, early negotiation of data sharing agreements among study teams would be ideal.
Recommendations: study design and operational details
An important consideration when planning to follow seroconverters is to determine how long to follow them within the context of the parent study and when to ask them to enroll in a seroconverter rollover study. The timing of transition into a rollover study impacts the number of participants recruited and long-term retention. Increasing retention (i.e., the proportion of all seroconverters in a parent study that roll over into the seroconverter study) is crucial to obtain sufficient sample size for comparative analysis. There are presently insufficient data on retention because many parent studies are ongoing and remain blinded, so it is premature to recommend an optimal time point for transition from parent to rollover studies. However, anecdotally, retention is higher and easier when seroconverters are followed within the context of the parent study for some period of time. Consent for remaining in an HIV prevention study in the event of seroconversion can be obtained from all participants at the beginning of the parent study, but consent for enrollment in a long-term seroconverter follow-up study must be obtained separately. Also, follow-up visits specific to seroconverters can be coordinated with regular study visits, making it more convenient for the participants and further promoting retention.
Following seroconverters within the context of the parent studies for a limited period also facilitates the capture of critical early postdiagnosis time point data; early time points, evaluations, and events may pertain to the objectives of the parent study. The MTN-015 study team reported that enrollment delays have occurred while HIV diagnoses are confirmed. Therefore, the MTN and other groups incorporated collection of early postdiagnosis samples into the parent protocols. Another strategy for increasing retention in both the parent study at the time of HIV diagnosis and enrollment into a rollover study is to have a dedicated team of counselors meet with participants who are diagnosed with HIV infection, as was done during the CAPRISA 004 study when participants were asked to enroll in Tenofovir gel Research for Advancing Prevention Science (TRAPS). HIV diagnosis is a difficult and challenging time both for the participants and the counselors/clinicians who work with them.
Counseling by a trained, dedicated team provides needed support and encouragement to remain on-study.
Building short-term seroconverter follow-up into the parent study promotes retention at the point of HIV diagnosis, allows time for obtaining consent for the rollover study, and facilitates collection of clinical data and specimens during early postdiagnosis time points, but long-term follow-up of seroconverters is costly and difficult to budget. Enrolling seroconverters from multiple parent studies into a single or a few seroconverter rollover studies may be more efficient and logistically feasible. On the basis of these considerations the SSG makes the protocol development, implementation, and timing recommendations in Table 5 . When developing a seroconverter rollover study and determining the optimal point of enrollment transition, the desire to ensure retention and capture early time points postdiagnosis has to be weighed against any potential gain in efficiency and cost savings of a rollover study.
Duration of follow-up postdiagnosis would need to vary by necessity, depending on the objectives of the parent and rollover studies. For example, questions regarding acute infection and correlates of harm and protection would require a short duration of follow-up, perhaps until participants reach viral set point. Those studies looking at disease progressions might follow participants until initiation of treatment. Studies looking at response to treatment or comorbidities such as chronic inflammation would necessitate a longer duration of follow-up. To mitigate the costs of an extended follow-up period, the frequency of visits would decrease over time. Potentially, novel and inexpensive point-of-care testing technologies could be incorporated to save cost and decrease burden on participants and clinics.
Recommendations: study objectives
The studies were compared to determine the common study objectives that would require follow-up of seroconverters, and to recommend a core set of these objectives for inclusion in all protocols that follow seroconverters (both parent and rollover studies). Delineation of a core set of objectives would facilitate protocol development and future cross-study analyses of clinical and laboratory data. The SSG found there were a few objectives that were common to many studies, and also identified some objectives that are currently included in two to four studies, but whose inclusion in future studies would be recommended (see Table 5 ).
The most common objectives shared across all protocols were to describe and compare the virological, immunological, and clinical course of HIV disease among seroconverters in active and placebo arms and to assess drug resistance; these objectives are included in the core set of recommended objectives. Although most studies collect behavioral risk information, very few have objectives related to behavioral risk. Although these objectives are not common, they would be recommended for inclusion in a core set of objectives. Similarly, although development of a specimen repository is a specific objective in only four studies, it is recommended as one of the core objectives. An evaluation of response to ART is also recommended, as selected drug resistance (owing to oral or topical antiretroviral-based PrEP), or disease progression modulation (via vaccine induction), may impact the natural history of treated and untreated disease. There were many objectives that were common to only a small number of studies (one to three), but would not be suitable for inclusion in a core set of objectives. These objectives would be considered to be study-specific, and are examples of objectives that a protocol team might choose to include in addition to the recommended core objectives as appropriate (see Supplemental Digital Content 1 and 2, http://links.lww. com/QAD/A297, detailed objectives of each protocol).
One might expect differences between vaccine and PrEP (microbicide and oral) protocols, but many similarities were found, indicating that a core set of seroconverterrelated objectives could be used in vaccine and PrEP studies. Furthermore, as uptake of oral PrEP increases and vaccine or other biomedical prevention studies allow for or provide PrEP, rollover studies that include participants from vaccine studies may need to evaluate the effects of PrEP on seroconversion and other postseroconversion endpoints.
Recommendations: sample collections and assessments
To facilitate analysis of clinical and laboratory data across studies, the protocols were compared to determine the common sample collections/assessments and to develop a core set that would be recommended for inclusion in all studies that follow seroconverters. We found that the samples collected varied across protocols, but those supporting the common objectives described above (whole blood, serum/plasma, and PBMCs), urine for pregnancy testing, and various genital secretions and/or biopsies are collected for most studies (Table 4 ) and would be recommended for inclusion in a core set of samples.
Behavioral assessments are collected in most studies both before and after diagnosis, but will pose particular challenges to cross-protocol analysis. The specific behavioral assessments, time frame for reporting, method of administration, and scales all vary across protocols, impeding cross-protocol comparison. Although acknowledging that no gold standard exists for behavioral assessments, development of best practices would facilitate both cross-protocol comparison and development of future protocols.
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Component Recommendations
Development and implementation of seroconverter studies
Develop network-specific or cross-network seroconverter studies for the long-term follow-up of study participants who seroconvert while participating in a network prevention study Timing of enrollment into seroconverter rollover studies Follow seroconverters in the short-term with in the context of the parent study before or concurrent with rollover into a seroconverter follow-up study Obtain consent for short-term and long-term follow-up postseroconversion, including the collection of samples for future genomic testing, at the time of enrollment Study objectives Develop for all prevention trials and all seroconverter rollover studies a core set of objectives; allow study teams to add study-specific objectives as necessary. Ideally, specimens (e.g. blood, cells, and genital secretions) should be banked in ample volumes for future assays. Although only three rollover protocols (MTN-015, HVTN 403, and HVTN 404) have specific study objectives for developing a repository of specimens for future analysis, most of the protocols store samples for future testing at the site or at a central repository. Most commonly stored are serum/plasma and cryopreserved PBMCs; collection and repository storage of these samples is recommended. Acknowledging that storage of such specimens is particularly costly and poses additional challenges in international settings, such a repository would be high-yield for answering both current and future research questions, many of which may be exploratory and/or not fully developed at the time of protocol conduct. Collection and storage of other sample types could be added to meet study-specific objectives.
Maximum blood draw volumes varied widely, ranging from 20 to 250 ml. It is unclear what factors contributed to this range, but reports from study teams suggested that local restrictions, cultural norms, and ethical considerations may be a limiting factor. It has been reported that some African communities believe a loss of blood leads to a loss of energy, immune function, and/or virility, or that it might be used in magic [44] [45] [46] [47] . Culturally sensitive training for site staff and participants may be required to support collection of blood in volumes sufficient for realtime and future testing, Some investigators report that there have been challenges to obtaining open-ended approval for genomic studies from national/local ethics committees, which may require more specific analysis plans and details for future testing than are typically needed for regulatory approval at US domestic sites. Ideally, collection of genomic information would be included in a core set of sample collections/assessments, although regulatory requirements may prove to be challenging. [48] . Most seroconverters do experience clinical symptoms attributable to acute HIV infection, but they do not always realize or report it [49] . Therefore, frequent HIV testing also has the advantage of identifying more participants during acute infection. Also, HIV testing reduces the potential for prolonged exposure to incompletely suppressive ART in the face of occult/ undetected acute/primary HIV infection. We found that HIV antibody testing is usually done on a monthly or quarterly basis; testing less frequently than monthly not only complicates estimation of seroconversion date but could also increase seroconverters' exposure to suboptimal treatment regimens. However, the cost and feasibility of monthly testing must also be considered. Table 5 . These examples are based on a hypothetical harmonization of current and recent protocols. Design of a collaborative rollover protocol would require careful consideration of the study objectives, the necessary samples/assessments, and the available resources.
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